Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.6 billion in assets with a track record of investing and returning capital since 2000.

learn more

Latest News

Syros Pharmaceuticals Closes $53 Million Series B Financing

October 27, 2014
WATERTOWN, MA, October 27, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies in cancer and other diseases, announced today that it has…

Actavis to Acquire Durata Therapeutics, Inc.

October 6, 2014
DUBLIN, Ireland and CHICAGO, Oct. 6, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Durata Therapeutics, Inc. (NASDAQ: DRTX), an innovative pharmaceutical company focused on the…

Dermira Prices Initial Public Offering

October 2, 2014
REDWOOD CITY, Calif., October 2, 2014 – Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today…